On Air Now

Current Show

America Now   8:00 PM - 11:00 PM

Call America Now at 877-927-2639 between 5pm and 8pm

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI

Weather

Current Conditions(Wausau,WI 54403)

More Weather »
46° Feels Like: 46°
Wind: W 0 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Clear 37°

Tomorrow

Sunny 65°

Wed Night

Clear 41°

GSK's Crohn's disease treatment fails in Phase III trial

The signage for the GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor
The signage for the GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor

LONDON (Reuters) - British pharmaceutical group GlaxoSmithKline Plc said vercirnon, a drug it was developing to treat Crohn's disease and licensed from ChemoCentryx, had failed in a late-stage clinical trial.

The medicine, which GSK licensed from the California-based company in 2010, did not improve the incidence of adverse events in patients when measured against a placebo, GSK said on Friday, and there was a trend for overall adverse events to increase as dosage levels increased.

The trial failure wiped as much as $242 million, or nearly half, from ChemoCentryx's value. Its shares were trading down 36 percent at $7.47 at 1438 GMT. GSK's shares were up 0.3 percent at 1,672 pence, underperforming a 0.7 percent stronger FTSE 100 index.

"The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease," said Paul-Peter Tak, senior vice president of GSK's immuno-inflammation research and development.

The company said new recruitment and dosing in the ongoing clinical trial had been suspended pending further review of the results.

Vercirnon, a type of drug called an antagonist, was being developed by GSK for the potential treatment of inflammatory bowel diseases, such Crohn's disease, a condition with symptoms such as persistent diarrhea and abdominal pain.

(Reporting by Paul Sandle; editing by David Evans)

Comments